iBio, Inc. Announces Proposed Public Offering Newark, Del.

iBio, Inc. Announces Proposed Public Offering

Newark, Del., April 22, 2013 /PRNewswire/ iBio, Inc.

(NYSE MKT: IBIO) today announced that it is offering shares of its

common stock and common stock purchase warrants in an underwritten public

offering. The offering is subject to market and other conditions, and there can

be no assurance as to whether or when the offering may be completed, or as to

the actual size or terms of the offering.

Roth Capital Partners, LLC is acting as the sole manager for the offering.

iBio plans to use proceeds of the offering for working capital,

including further development of iBio s product candidates and proprietary

technology, business development and for other general corporate purposes.

The securities described above are being offered by iBio pursuant to a

registration statement previously filed with and subsequently declared

effective by the Securities and Exchange Commission ( SEC ). A preliminary

prospectus supplement relating to the offering has also been filed with the SEC

and is available on the SEC s website at http://www.sec.gov.

This press release shall not constitute an offer to sell or the

solicitation of an offer to buy any of the securities described herein, nor

shall there be any sale of these securities in any state or jurisdiction in

which such offer, solicitation or sale would be unlawful prior to registration

or qualification under the securities laws of any such state or jurisdiction.

Copies of the preliminary prospectus supplement and accompanying base

prospectus relating to this offering may be obtained from Roth Capital

Partners, LLC, 888 San Clemente Drive, Newport Beach, CA 92660, (800) 678-9147

or email: rothecm@roth.com or by accessing the SEC s website, www.sec.gov.

iBio develops and offers product applications of its iBioLaunch and

iBioModulator platforms, providing collaborators full support for turn-key

implementation of its technology for both proprietary and biosimilar products.

Additionally, iBio is developing select product candidates that have been

derived from the iBioLaunch platform. The iBioLaunch platform is a proprietary,

transformative technology for development and production of biologics using

transient gene expression in unmodified green plants. The iBioModulator platform

is complementary to the iBioLaunch platform and is designed to

significantly improve vaccine products with both higher potency and

greater duration of effect. The iBioModulator platform can be used with any

recombinant expression technology for vaccine development and production.

Further information is available at: www.ibioinc.com.

Forward-Looking Statements

Statements included in this news release

related to the offering and iBio, Inc. may constitute forward-looking

statements within the meaning of the Private Securities Litigation Reform Act

of 1995. Such statements including the intended use of proceeds resulting from

successfully closing the offering involve a number of risks and uncertainties

such as public market conditions and satisfaction of customary closing

conditions related to a public offering of securities. Further information on

potential risk factors that could affect the Company s business operations and

financial results can be found in the prospectus and the reports the Company has

filed with the Securities and Exchange Commission.